Clinical trials: Breakthrough Bleeding
- Condition Breakthrough Bleeding
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Abnormal Uterine Bleeding
Management of Abnormal Uterine Bleeding
Abnormal uterine bleeding "AUB" describes all abnormal forms of menstrual bleeding which may result from several causes including anovulation, problems related to pregnancy, infections, vaginal and cervical abnormalities, uterine…
- Trial name
- NCT06369012
- Testing
- Mefenamic acid 500 mg
- Where
- Egypt
- Volunteers
- 130 people
- Sponsor
- Egymedicalpedia
Dysfunctional Uterine Bleeding
COMPARISON OF A NEW FORMULATION OF GOSERELIN (Pepti 3.6 mg) to Zoladex® 3.6 mg
The comparator drug (Zoladex 3.6 mg) is approved for use as a thinning agent for the endometrium prior to endometrial ablation. The dosing recommendation is one or two depots with each depot given four weeks apart.
- Trial name
- NCT04428684
- Testing
- Pepti 3.6 mg
- Where
- 5 sites in Ukraine
- Volunteers
- 80 people
- Sponsor
- Peptigroupe Inc.